InterStim™ systems have been implanted in over 325,000 patients, and evaluated in more than 1,000 published clinical articles, including long-term (5-year) data for urinary incontinence, retention, and fecal incontinence.*VIEW PRODUCTS
With the InterStim™ systems, the implanted neurostimulator and lead electrically stimulate the sacral nerve. This is thought to normalize neural communication between the bladder and brain and between the bowel and brain.1,2 Unlike oral medications that target the muscular component of bladder control, the InterStim™ systems offer control of symptoms through direct modulation of the nerve activity.1,2
One key advantage of this therapy is that it can be tested for potential success prior to implantation. The evaluation provides an opportunity to find out whether adequate symptom reduction is achieved in as few as three to seven days. Complications can occur with the evaluation, including tissue damage, infection, and technical problems with the device. Patients should be instructed on operating the programmer and given precautions related to the evaluation.
The most common adverse events experienced during clinical studies of patients with SNM included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
Data from InterStim Sales Analysis. Medtronic, Inc. April 2020.
Restored bladder function defined as ≥50% reduction in dysfunctional voiding symptoms from baseline. Restored bowel function is defined as ≥50% reduction in chronic fecal incontinence episodes.
Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11-18.
Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100:959–968.
Yeaw J, Benner J, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):724-736.
Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931-937.
Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association (AUA). J Urol. 2015 May;193(5):1572-80.
Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at 12 months in subjects with symptoms of OAB. Neurourol Urodyn. 2014. doi:10.1002/nau.22707.
Medtronic InterStim Therapy Clinical Summary, 2018.
Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014 Aug;109(8):1141-1157.
Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.